EchoNous Named to Fast Company’s Annual List of the World’s 50 Most Innovative Companies for 2022
Leading developer of AI-guided ultrasound technology joins the ranks of Canva, Microsoft, SpaceX, and more…
Leading developer of AI-guided ultrasound technology joins the ranks of Canva, Microsoft, SpaceX, and more…
SEATTLE–(BUSINESS WIRE)–#beauty–For the month of March, FashWire (App Store and Google Play) and GlossWire (App…
Get the new iPhone SE for $30 with eligible trade-in, available for pre-order on March…
BRISTOL, Conn.–(BUSINESS WIRE)–Barnes Group Inc. (NYSE: B), a global provider of highly engineered products, differentiated…
Net income for the fourth quarter of $17 million and $90 million for full-year 2021…
PASADENA, Calif.–(BUSINESS WIRE)–$HLGN #ArtificialIntelligence–Heliogen, Inc. (“Heliogen”) (NYSE: HLGN), a leading provider of AI-enabled concentrated solar…
PITTSBURGH–(BUSINESS WIRE)–$SMSI #commsuite–Smith Micro Software, Inc. (NASDAQ: SMSI) (“Smith Micro” or the “Company”) today reported…
Fourth quarter net sales of $75.3 million, up 40.2% year-over-year Full year net sales of…
– Revenue Growth for the Fourth Quarter and Full Year Driven by Continued Strength Across…
Achieves 3% Revenue Growth in the First Quarter Fiscal 2022 Compared to Prior Year, Driven…
IRVINE, Calif.–(BUSINESS WIRE)–Tilly’s, Inc. (NYSE: TLYS, the “Company”) today announced financial results for the fourth…
COLUMBIA, Md.–(BUSINESS WIRE)–$BBAI–BigBear.ai (NYSE: BBAI), a leading provider of AI-powered analytics and cyber engineering solutions,…
ANAHEIM, Calif.–(BUSINESS WIRE)–$WLDN–Willdan Group, Inc. (“Willdan”) (Nasdaq: WLDN), a provider of professional, technical and consulting…
Q4 total revenue year-over-year growth of 13.3% to $31.9 million; full year total revenue growth…
NEW YORK–(BUSINESS WIRE)–#KBRA–KBRA assigns preliminary ratings to eight classes of Progress Residential 2022-SFR2 (Progress 2022-SFR2)…
BEDFORD, Mass., March 10, 2022 (GLOBE NEWSWIRE) — Homology Medicines, Inc. (Nasdaq: FIXX), a genetic…
Reached consensus with the FDA on the design and major details of the global Phase…
Data from interim analyses of Phase 2 OraGrowtH210 Trial and PK/PD OraGrowtH212 Trial evaluating oral…
SANTA MONICA, Calif., March 10, 2022 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (Nasdaq: OPNT), a…
CAP-1002 Cell Therapy Programs -Pivotal Phase 3, HOPE-3 Trial Initiation Underway- -Entered Exclusive Partnership with…